Skip to main content

Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine

Abstract

Background

Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC.

Methods

Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining resistin’s concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1 mRNA levels and rs1862513 polymorphism.

Results

Plasma resistin and CAP-1 mRNA levels were higher in CRC patients (p < 0.001 and p < 0.05, respectively), while resistin mRNA levels were lower (p < 0.001). Negative association existed among plasma resistin and HDL-C concentrations (ρ = − 0.280; p < 0.05). A model including age, body-mass index, HDL-C, low-density lipoprotein cholesterol (LDL-C), and plasma resistin concentrations as independent predictors of CRC showed very good diagnostic accuracy (AUC = 0.898). We found no associations of rs1862513 with the examined markers.

Conclusions

Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin’s secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters might be useful for prediction and prevention of CRC development.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Nyström M, Mutanen M. Diet and epigenetics in colon cancer. World J Gastroenterol. 2009;15:257–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One. 2013;8:e53916.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6:9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011;22:259–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. İclal G, Mehmet K, Yılmaz K, Müslüm A. Increased resistin serum concentrations in patients with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2013;5:189–93.

    Article  Google Scholar 

  6. Asgary S, SamsamShariat S, Ghorbani A, Keshvari M, Sahebkar A, Sarrafzadegan N. Relationship between serum resistin concentrations with metabolic syndrome and its components in an Iranian population. Diabetes Metab Syndr Clin Res Rev. 2015;9:266–70.

    Article  Google Scholar 

  7. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070–4.

    Article  CAS  PubMed  Google Scholar 

  8. Riondino S, Roselli M, Palmirotta R, Della-Morte D, Ferroni P, Guadagni F. Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol. 2014;20:5177–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Feng Z, Zhang H. Resistin and cancer risk: a mini-review. Endocrinol Metabol Syndrome. 2011;S4:003.

    Google Scholar 

  10. Dalamaga M. Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med. 2014;8:107–18.

    Article  CAS  PubMed  Google Scholar 

  11. Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control. 2015;26:257–68.

    Article  PubMed  Google Scholar 

  12. Mihajlovic M, Gojkovic T, Vladimirov S, Miljkovic M, Stefanovic A, Vekic J, et al. Changes in lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and paraoxonase-1 activities in patients with colorectal cancer. Clin Biochem. 2019;63:32–8.

    Article  CAS  PubMed  Google Scholar 

  13. Stevanovic M, Vekic J, Bogavac-Stanojevic N, Janac J, Stjepanovic Z, Zeljkovic D, et al. Significance of LDL and HDL subclasses characterization in the assessment of risk for colorectal cancer development. Biochem Med. 2018;28:503–13.

    Article  Google Scholar 

  14. Lu M, Zhan X. The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J. 2018;9:77–102.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Golubnitschaja O, Costigliola V. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3:14.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Tarkowski A, Bjersing J, Shestakov A, Bokarewa M. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2010;14:1419–31.

    Article  CAS  PubMed  Google Scholar 

  17. Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J, et al. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab. 2014;19:484–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yang G, Fan W, Luo B, Xu Z, Wang P, Tang S, et al. Circulating resistin levels and risk of colorectal cancer: a meta-analysis. Biomed Res Int. 2016;2016:1–11.

    CAS  Google Scholar 

  19. Munjas J, Sopić M, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Anđelković K, Jelić-Ivanović Z. Association of adenylate cyclase-associated protein 1 with coronary artery disease. Eur J Clin Investig. 2017;47:659–66.

    Article  CAS  Google Scholar 

  20. Cheng T, Zhan X. Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J. 2017;8:51–60.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper. EPMA J. 2016;7:23.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hashemi M, Bahari G, Tabasi F, Moazeni-Roodi A, Ghavami S. Association between rs1862513 and rs3745367 genetic polymorphisms of resistin and risk of cancer: a meta-analysis. Asian Pac J Cancer Prev. 2018;19:2709–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Vujovic A, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, Spasic S, Kotur-Stevuljevic J, Jelic-Ivanovic Z. Comparison of two RNA isolation methods for determination of SOD1 and SOD2 gene expression in human blood and mononuclear cells. Indian J Biotechnol. 2013;12:468–74.

    CAS  Google Scholar 

  24. Wang CH, Wang PJ, Hsieh YC, Lo S, Lee YC, Chen YC, et al. Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene. 2018;37:589–600.

    Article  CAS  PubMed  Google Scholar 

  25. Hsieh YY, Shen CH, Huang WS, Chin CC, Kuo YH, Hsieh MC, et al. Resistin-induced stromal cell-derived factor-1 expression through toll-like receptor 4 and activation of p38 MAPK/ NFκB signaling pathway in gastric cancer cells. J Biomed Sci. 2014;21:59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhang H, Zhou G. CAP1 (cyclase-associated protein 1) exerts distinct functions in the proliferation and metastatic potential of breast Cancer cells mediated by ERK. Sci Rep. 2016;6:25933.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Xie S, Shen C, Zhou S, Xiong M, Tan M, Song X, et al. Role of adenylate cyclase-associated protein 1 in cancers. Int J Clin Exp Med. 2018;11:3086–99.

    Google Scholar 

  28. Ono S. The role of cyclase-associated protein in regulating actin filament dynamics–more than a monomer-sequestration factor. J Cell Sci. 2013;126:3249–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286–90.

    Article  CAS  PubMed  Google Scholar 

  30. Danese E, Montagnana M, Minicozzi AM, Bonafini S, Ruzzenente O, Gelati M, et al. The role of resistin in colorectal cancer. Clin Chim Acta. 2012;413:760–4.

    Article  CAS  PubMed  Google Scholar 

  31. Song G, Wu X, Zhang P, Yu Y, Yang M, Jiao P, et al. High-density lipoprotein inhibits ox-LDL-induced adipokine secretion by upregulating SR-BI expression and suppressing ER stress pathway. Sci Rep. 2016;6:30889.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Rosso LG, Lhomme M, Merono T, Sorroche P, Catoggio L, Soriano E, et al. Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation. Atherosclerosis. 2014;237:652–60.

    Article  CAS  Google Scholar 

  33. Kunnari AM, Savolainen ER, Ukkola OH, Kesäniemi YA, Jokela MA. The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalpha. Regul Pept. 2009;157:57–63.

    Article  CAS  PubMed  Google Scholar 

  34. Ghaemmaghami S, Mohaddes S, Hedayati M, Mohammadi M, Dehbashi G. Resistin and visfatin expression in HCT-116 colorectal cancer cell line. Int J Mol Cell Med. 2013;2:143–50.

    PubMed  PubMed Central  Google Scholar 

  35. Munoz-Palomeque A, Guerrero-Ramirez MA, Rubio-Chavez LA, Rosales-Gomez RC, Lopez-Cardona MG, Barajas-Avila VH, et al. Association of RETN and CAP1 SNPs, expression and serum resistin levels with breast cancer in Mexican women. Genet Test Mol Biomarkers. 2018;22:209–17.

    Article  CAS  PubMed  Google Scholar 

  36. Gordon S, Plüddemann A. Tissue macrophages: heterogeneity and functions. BMC Biol. 2017;15:53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173–96.

    Article  CAS  PubMed  Google Scholar 

  38. Janssens JP, Schuster K, Voss A. Preventive, predictive, and personalized medicine for effective and affordable cancer care. EPMA J. 2018;9:113–23.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101:1286–91.

    Article  CAS  PubMed  Google Scholar 

  40. Ning S, Wei W, Li J, Hou B, Zhong J, Xie Y, et al. Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients. J Cancer. 2018;9:494–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, et al. The G/G genotype of a resistin single-nucleotide polymorphism at −420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 2004;75:678–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Osawa H, Tabara Y, Ohashi J, Kawamura R, Onuma H, Makino H. Is rs34861192 or rs1862513 a more promising variant for determining plasma resistin in an aged Japanese population? Diabetologia. 2010;53:795–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Onuma H, Tabara Y, Kawamura R, Ohashi J, Nishida W, Takata Y, et al. Dual effects of a RETN single nucleotide polymorphism (SNP) at −420 on plasma resistin: genotype and DNA methylation. J Clin Endocrinol Metab. 2017;102:884–92.

    Article  PubMed  Google Scholar 

Download references

Funding

This work was supported by a grant from the Ministry of Education, Science and Technological Development, Republic of Serbia (Project No. 175035).

Author information

Authors and Affiliations

Authors

Contributions

MM (corresponding author) performed laboratory measurements, statistical analysis, and wrote the first draft of the manuscript. AN, MS, MM, and AS contributed to experimental design and participated in laboratory analyses. DZ, BT, and ZS were involved in protocol development, patient recruitment, and data acquisition. JV and VSK provided intellectual guidance and critically reviewed the manuscript. AZ conceived and designed the study and critically reviewed the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Corresponding author

Correspondence to Marija Mihajlovic.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The entire study protocol was designed according to the Helsinki Declaration and approved by the local ethical committee (The Ethics committee of the Military Medical Academy; Ethics Committee reference no. 3000-1).

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mihajlovic, M., Ninic, A., Sopic, M. et al. Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine. EPMA Journal 10, 307–316 (2019). https://doi.org/10.1007/s13167-019-00178-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13167-019-00178-x

Keywords

  • Resistin
  • Adenylate cyclase-associated protein 1
  • High-density lipoprotein cholesterol
  • Paraoxonase-1 activity
  • Colorectal cancer
  • Predictive preventive personalized medicine